2.77 USD
▲+0.01+2.97%
盘后 2.65 -1.49%
2026-08-03
市值
$451.66M
市盈率
—
EPS
-1.84
股息率
—
52 周区间
1.26 – 4.23
成交量
2.71M
Beta
3.26
目标价
13.38
52W 低 1.2652W 高 4.23
价格走势
公司简介
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero...